Ellen Cavaleri
Investor Relations Kontakt bei LYRA THERAPEUTICS, INC.
Aktive Positionen von Ellen Cavaleri
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LYRA THERAPEUTICS, INC. | Investor Relations Kontakt | 01.01.2022 | - |
Public Communications Contact | 01.01.2022 | - |
Karriereverlauf von Ellen Cavaleri
Ehemalige bekannte Positionen von Ellen Cavaleri
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KADMON HOLDINGS, INC. | Investor Relations Kontakt | - | - |
Ausbildung von Ellen Cavaleri
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Investor Relations Contact | 2 |
Public Communications Contact | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Ellen Cavaleri
- Erfahrung